Australian Medical Angels

Co-founders Dr Amandeep Hansra and Dr Mian Bi built the syndicate and set its investment strategy, according to the firm's own origin account. The group draws on its base of more than 1,000 clinical practitioners to surface and diligence health-tech opportunities, though the specific internal investment-committee structure has not been publicly disclosed. Hansra titles himself as Co-Founder and the public face of the firm's mission.

The syndicate's sourcing rests on a network of over 1,000 clinician members and an extended group of 40,000 medical contacts, giving it visibility into innovations that practising doctors encounter. Co-founder Amandeep Hansra describes the origin as connecting doctors with capital to health-tech founders who lacked seed funding. Portfolio companies also gain access to clinical validation and distribution through this network.

Medical Angels operates as an angel investment syndicate layered with a new venture capital arm. It started in 2017 as a member-based syndicate of Australian clinicians and launched its first dedicated fund in 2026 — Medical Angels Venture Fund I, a $40M ESVCLP. The firm is not a family office; it functions as a thematic asset manager drawing capital from a broad clinician membership.

The group focuses on early-stage health-tech companies, explicitly positioning itself between the friends-and-family round and larger venture capital funds that write cheques above $1 million. Its 2026 fund carries an early-stage mandate consistent with the syndicate's historical deal size. The firm has backed companies in telehealth, obstetrics, healthcare marketplaces, and VR.

The firm has not published a list of excluded sectors. Its entire disclosed portfolio and public commentary centre on health and medical technology. No non-health technology investments appear in available sources.

Medical Angels describes its role as bridging the gap between seed-stage founders and later-stage VC funds, which suggests syndicate rounds typically precede or run parallel to institutional capital. The firm has not publicly disclosed specific co-investment partnerships or GP relationships.